Drug duo targets tough tumors in early trial

NCT ID NCT03878095

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no longer recruiting, and results are being analyzed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cholangiocarcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID NEOPLASM REFRACTORY CHOLANGIOCARCINOMA REFRACTORY MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, 06611, United States
UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.